Introduction Autism spectrum disorder (ASD) is an early-onset disorder with a prevalence of
1% among children and reported disability-adjusted life years of 4.31 million. Irritability is a …

Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder. Approximately,
around 2% to 3% percent of the general population experience symptoms of OCD over the …

Despite recent progress, the challenges in drug discovery for schizophrenia persist.
However, computational drug repurposing has gained popularity as it leverages the wealth …

Minocycline is an FDA-approved secondary-generation tetracycline antibiotic. It is a
synthetic antibiotic having many biological effects, such as antioxidant, anti-inflammatory …

Multiple sclerosis (MS) is a chronic, autoimmune, demyelinating disease of the central
nervous system (CNS). Microbes, including bacteria and certain viruses, particularly Epstein …

Major depression is an established risk factor for subsequent dementia, and depression in
late life may also represent a prodromal state of dementia. Considering current challenges …

Pexidartinib (PLX3397) is a small molecule receptor tyrosine kinase inhibitor of colony
stimulating factor 1 receptor (CSF1R) with moderate selectivity over other members of the …

Background: Major depressive disorder is often resistant to first-line treatment, with around
30% failing to respond to traditional therapy. Treatment-resistant depression results in …

Autism spectrum disorder (ASD1) is a behaviorally defined syndrome encompassing a
markedly heterogeneous patient population. Many ASD subjects fail to respond to the 1st …

Background Bipolar disorder (BD) presents significant challenges in drug discovery,
necessitating alternative approaches. Drug repurposing, leveraging computational …